Information Provided By: 
Fly News Breaks for June 15, 2018
VSTM
Jun 15, 2018 | 07:06 EDT
Cantor Fitzgerald analyst Mara Goldstein believes Verastem's 7.1M share placement to a single institution removes an overhang on the shares. The raise bumps the company's cash to at least $140M, which will go a long way in removing an overhang on the shares ahead of the FDA action date of October 5, Goldstein tells investors in a research note. She continues to believe that the market for duvelisib is larger than Verastem's valuation suggests. Goldstein keeps an Overweight rating on the shares with a $17 price target.
News For VSTM From the Last 2 Days
VSTM
Apr 18, 2024 | 16:05 EDT
Verastem Oncology "announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. "
